Iamgold Corporation Ordinary Shares vs Regeneron Pharmaceuticals Inc — how do they compare? Iamgold Corporation Ordinary Shares trades at $18.63 (market cap $10.49B), while Regeneron Pharmaceuticals Inc trades at $742.38 (market cap $76.14B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 7.3× Iamgold Corporation Ordinary Shares's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while Iamgold Corporation Ordinary Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Iamgold Corporation Ordinary Shares for 0 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| IAG | REGN | |
|---|---|---|
Market Cap | $10.49B | $76.14B |
Volume | 3,160,902 | 500,239 |
Sector | Basic Materials | Health |
52-Week High | $24.57 | $852.03 |
52-Week Low | $10.96 | $557.73 |
Typical Hold Time | 0 Days | 107 Days |
Enterprise Value | $10.53B | $70.85B |
Dividend Yield | — | 0.51% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Regeneron Pharmaceuticals (REGN) trades at $739.28, down 0.38% on the day, with a bearish technical signal and neutral oscillators. The company shows strong fundamentals with a P/E of 18.3, net income margin of 27.86%, and consistent earnings beats in recent quarters. Recent news highlights a major $8 billion immunology alliance expansion with Sanofi, including a $1 billion upfront payment, reinforcing its pipeline strength and long-term growth prospects.
The outlook remains positive driven by robust profitability, strategic collaborations, and a bullish analyst consensus with a $849.84 price target. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. Institutional sentiment is strong with no sell ratings, supporting a favorable risk-reward profile for investors seeking exposure to biopharmaceutical innovation.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
IAMGOLD is a gold mining company with operations in Canada. It also explores and develops gold properties.
Read more on IAG →Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →